Nancy Hutson Net Worth

The estimated Net Worth of Nancy J Hutson is at least 779 千$ dollars as of 20 May 2024. Nancy Hutson owns over 5,000 units of Endo International plc stock worth over 25,403$ and over the last 13 years he sold ENDP stock worth over 433,354$. In addition, he makes 320,000$ as Independent Director at Endo International plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nancy Hutson ENDP stock SEC Form 4 insiders trading

Nancy has made over 19 trades of the Endo International plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ENDP stock worth 31,900$ on 20 May 2024.

The largest trade he's ever made was exercising 105,000 units of Endo International plc stock on 15 October 2021 worth over 363,300$. On average, Nancy trades about 4,371 units every 50 days since 2012. As of 20 May 2024 he still owns at least 86,818 units of Endo International plc stock.

You can see the complete history of Nancy Hutson stock trades at the bottom of the page.

Nancy Hutson biography

Dr. Nancy J. Hutson Ph.D. is Independent Directors of Endo International Public Limited Company., since 2009 . She has been a member of the Board of Directors since February 2014 and is Chair of Endo’s Compliance Committee and a member of Endo’s Nominating & Governance Committee. Dr. Hutson retired from Pfizer, Inc. (Pfizer) in 2006 after spending 25 years in various research and leadership positions, most recently having served as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer’s pharmaceutical R&D site, known as Groton/New London Laboratories. At Pfizer, she led 4,500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She is currently a Director of BioCryst Pharmaceuticals, Inc. and PhaseBio Pharmaceuticals, Inc. Dr. Huston previously served as Director of Cubist Pharmaceuticals until 2015 and Inspire Pharmaceuticals, Inc. until 2011. From 2009 until February 2014, Dr. Hutson was a Director of Endo Health Solutions Inc. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT. Dr. Hutson holds a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. degree from Vanderbilt University. Dr. Hutson’s qualifications to serve on the Board of Endo include, among others, her in-depth knowledge and understanding of the complex research, drug development and business issues facing pharmaceutical companies.

What is the salary of Nancy Hutson?

As the Independent Director of Endo International plc, the total compensation of Nancy Hutson at Endo International plc is 320,000$. There are 10 executives at Endo International plc getting paid more, with Paul Campanelli having the highest compensation of 13,118,300$.

How old is Nancy Hutson?

Nancy Hutson is 70, he's been the Independent Director of Endo International plc since 2009. There are 3 older and 13 younger executives at Endo International plc. The oldest executive at Endo International plc is Michael Hyatt, 74, who is the Independent Director.

What's Nancy Hutson's mailing address?

Nancy's mailing address filed with the SEC is C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA, GA, 30005.

Insiders trading at Endo International plc

Over the last 11 years, insiders at Endo International plc have traded over 3,455,441$ worth of Endo International plc stock and bought 152,347 units worth 3,901,804$ . The most active insiders traders include Silva Rajiv De、Paul Campanelli、Shane Cooke. On average, Endo International plc executives and independent directors trade stock every 36 days with the average trade being worth of 12,163$. The most recent stock trade was executed by Patrick A Barry on 29 March 2022, trading 59,298 units of ENDP stock currently worth 17,351$.

What does Endo International plc do?

Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.

Complete history of Nancy Hutson stock trades at Biocryst Pharmaceuticals、Clearside Biomedical Inc、Endo International plc、PhaseBio Pharmaceuticals

Endo International plc executives and stock owners

Endo International plc executives and other stock owners filed with the SEC include:

• Paul Campanelli,
  Chairman of the Board
• Terrance Coughlin,
  Chief Operating Officer, Executive Vice President
• Blaise Coleman,
  Pres, CEO & Director
• Blaise Coleman,
  President, Chief Executive Officer, Director
• Matthew Maletta,
  Executive Vice President, Chief Legal Officer
• Patrick Barry,
  Executive Vice President and Chief Commercial Officer, U.S. Branded Business
• Patrick A. Barry,
  Exec. VP & Pres of Global Commercial Operations
• Mark T. Bradley,
  Exec. VP & CFO
• Roger Kimmel,
  Senior Independent Director
• Shane Cooke,
  Independent Director
• William Montague,
  Independent Director
• Nancy Hutson,
  Independent Director
• Michael Hyatt,
  Independent Director
• M. Christine Smith,
  Independent Director
• Mark Barberio,
  Independent Director
• Jack Boyle,
  Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer, Controller
• Rahul Garella,
  Executive Vice President, International Pharmaceuticals
• Domenico Ciarico,
  Executive Vice President and Chief Commercial Officer, Sterile and Generics
• Joseph A. Barbarite,
  Exec. VP of Global Quality and Compliance
• Tracy Basso,
  Chief HR Officer
• Susan Williamson,
  Sr. VP & Chief Compliance Officer
• Laure E. Park,
  Sr. VP of Investor Relations & Corp. Affairs
• Ruth Thorpe,
  Sr. VP of Information Technology & Chief Information Officer
• Robert Polke,
  Exec. VP & Global Head of Operations
• Arthur J Higgins,
  Director
• Douglas S Ingram,
  Director
• Hemanth Jacob Varghese,
  Pres. International Pharma
• Suketu Upadhyay,
  EVP, Chief Financial Officer
• Antonio R Pera,
  President, Par Pharmaceutical
• Joseph Ciaffoni,
  President, U.S. Branded Pharma
• Carrie Ann Nichol,
  SVP, Controller & CAO
• Mark T. Bradley,
  EVP, Chief Financial Officer
• Frank B. Raciti,
  VP, Controller and CAO
• Daniel Rudio,
  Vice President, Controller
• Sharad Mansukani,
  Director
• William Spengler,
  Director
• Silva Rajiv De,
  President & CEO
• John Delucca,
  Director
• Brian Lortie,
  President Branded Pharma
• Susan Hall,
  EVP, CSO, Global Head of R&D
• Caroline B Manogue,
  Exec. V.P., CLO & Secy
• Camille Farhat,
  President, AMS, Inc.
• Ivan P. Gergel,
  EVP, R&D and CSO
• Donald W De Golyer,
  Chief Operating Officer,Pharma
• Mary Christine Smith,
  Director
• George Apostol,
  EVP, Global R&D
• Jennifer M Chao,
  Director
• James Patrick Tursi,
  Executive VP, Global R&D